Myeloid Therapeutics
PrivateLast Round
Series B
May 14, 2026
Total Funding Raised
$245M
Company Overview
CREATE Medicines is a biotechnology company that develops mRNA-based in vivo cell therapies for the treatment of cancer, autoimmunity, and fibrosis.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery, Precision Medicine, Clinical Trials
Business Model
B2B
Customer Profile
Services & Consulting
AI Layer
Non-AI
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Myeloid Therapeutics Comps
Public and private peers based on sector, stage, and business model.
| Company | Status | Est. Valuation | Rev Multiple |
|---|---|---|---|
| OpenAI | Private | $86.0B | ~40x |
| Cohere | Private | $5.0B | -- |
| Competitor 1 | Public | $XX.XB | XXx |
| Competitor 2 | Public | $XX.XB | XXx |
Myeloid Therapeutics Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series B | May 14, 2026 | ||||
| Series A Extension | May 18, 2023 | ||||
| Series A | Jan 6, 2021 |
Key People
Founding team and executive leadership
Myeloid Therapeutics Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Newpath Partners | Series B, Series A, Series A Extension |
| ARCH Venture Partners | Series A Extension, Series B |
| Hatteras Venture Partners | Series A, Series B, Series A Extension |
| Moore Strategic Ventures | Series A Extension |
| ARCH Venture Partners | Series A Extension |
| Alexandria Venture Investments | Series B, Series A Extension, Series A |
| Hatteras Investment Partners | Series A Extension |
Market signals
Structured signals derived from secondary market and firmographic data.
- Oct 29, 2025
Presented preclinical data at the Cold Spring Harbor Laboratory Meeting.
- Oct 29, 2025
Announced new preclinical data for the RetroT gene-integration system.
Myeloid Therapeutics Filings
SEC and related filings with document metadata.
| Typed | Date | Amount Offered | Amount Sold | Filling | Pages | Download |
|---|---|---|---|---|---|---|
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Frequently Asked Questions
Common questions about Myeloid Therapeutics's valuation, stock price, and market status.